keyword
MENU ▼
Read by QxMD icon Read
search

Cancer ovarian

keyword
https://www.readbyqxmd.com/read/28743036/recist-response-and-variation-of-circulating-tumour-cells-in-phase-1-trials-a-prospective-multicentric-study
#1
Christophe Massard, Isabelle Borget, Françoise Farace, Sandrine Aspeslagh, Marie-Cécile Le Deley, Christophe Le Tourneau, François-Clement Bidard, Jean-Yves Pierga, Veronique Dieras, Paul Hofman, Jean-Philippe Spano, Charles Ferte, Ludovic Lacroix, Jean-Charles Soria
BACKGROUND: Circulating tumour cell (CTC) counting could be a new biomarker for better evaluation of tumour response to molecules tested in phase I trials. PATIENTS AND METHODS: Consenting patients with advanced metastatic cancer referred to various phase I units were enrolled prospectively in this study. CTCs from 7.5 ml of whole blood drawn at baseline and after starting experimental therapy were counted using the CellSearch system, and tumour response was assessed using RECIST 1...
July 22, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28742796/leukocyte-telomere-length-and-renal-cell-carcinoma-survival-in-two-studies
#2
Catherine L Callahan, Kendra Schwartz, Julie J Ruterbusch, Brian Shuch, Barry I Graubard, Qing Lan, Richard Cawthon, Andrea A Baccarelli, Wong-Ho Chow, Nathaniel Rothman, Jonathan N Hofmann, Mark P Purdue
BACKGROUND: Leukocyte telomere length (LTL) is a potential biomarker of cancer prognosis; however, evidence for renal cell carcinoma (RCC) is inconsistent. METHODS: We investigated LTL and RCC-specific survival among 684 cases from the US kidney cancer study (USKC) and 241 cases from the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO). Leukocyte telomere length was measured by quantitative polymerase chain reaction, and hazard ratios (HRs) and 95% confidence intervals (CIs) computed using multivariable Cox models...
July 25, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28742794/the-cost-effectiveness-of-screening-for-ovarian-cancer-results-from-the-uk-collaborative-trial-of-ovarian-cancer-screening-ukctocs
#3
Usha Menon, Alistair J McGuire, Maria Raikou, Andy Ryan, Susan K Davies, Matthew Burnell, Aleksandra Gentry-Maharaj, Jatinderpal K Kalsi, Naveena Singh, Nazar N Amso, Derek Cruickshank, Stephen Dobbs, Keith Godfrey, Jonathan Herod, Simon Leeson, Tim Mould, John Murdoch, David Oram, Ian Scott, Mourad W Seif, Karin Williamson, Robert Woolas, Lesley Fallowfield, Stuart Campbell, Steven J Skates, Mahesh Parmar, Ian J Jacobs
BACKGROUND: To assess the within-trial cost-effectiveness of an NHS ovarian cancer screening (OCS) programme using data from UKCTOCS and extrapolate results based on average life expectancy. METHODS: Within-trial economic evaluation of no screening (C) vs either (1) an annual OCS programme using transvaginal ultrasound (USS) or (2) an annual ovarian cancer multimodal screening programme with serum CA125 interpreted using a risk algorithm (ROCA) and transvaginal ultrasound as a second-line test (MMS), plus comparison of lifetime extrapolation of the no screening arm and the MMS programme using both a predictive and a Markov model...
July 25, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28742659/laparoscopy-compared-with-laparotomy-for-debulking-ovarian-cancer-after-neoadjuvant-chemotherapy
#4
Fabio Martinelli, Antonino Ditto, Giorgio Bogani, Francesco Raspagliesi
No abstract text is available yet for this article.
August 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28742202/does-the-age-affect-the-efficacy-of-angiogenesis-inhibitors-in-ovarian-cancer-a-meta-analysis-of-randomized-controlled-trials
#5
H Miao, C-X Miao, J Han, N Li
OBJECTIVE: There are limited data on the role of angiogenesis inhibitors (AIs) in the treatment of elderly patients with ovarian cancer. We aim to assess the overall efficacy of AIs-containing regimens in the treatment of ovarian cancer in this patients group. MATERIALS AND METHODS: Databases and abstracts presented meetings up to November 2016 were searched to identify relevant studies. Prospective randomized controlled trials (RCTs) investigating therapies with or without AIs in elderly patients with ovarian cancer were included in the present study...
July 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28742191/high-progesterone-levels-during-the-luteal-phase-related-to-the-use-of-an-aromatase-inhibitor-in-breast-cancer-patients
#6
C Alviggi, R Marci, R Vallone, A Conforti, F Di Rella, I Strina, S Picarelli, P De Rosa, M De Laurentiis, C Yding Andersen, G De Placido
OBJECTIVE: To evaluate the hormonal profile in three breast cancer patients who underwent controlled ovarian stimulation in the presence of the aromatase inhibitor letrozole. PATIENTS AND METHODS: In IVF University referral center, a case series of three breast cancer patients who underwent controlled ovarian stimulation (COS) with recombinant FSH and letrozole were investigated. Ovulation was induced with hCG (case No. 1) or with GnRH agonist (case No. 2-3). The primary outcome of our study was the detection of progesterone levels in the luteal phase...
July 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28741395/predictive-value-of-the-age-adjusted-charlston-co-morbidity-index-on-peri-operative-complications-adjuvant-chemotherapy-usage-and-survival-in-patients-undergoing-debulking-surgery-after-neo-adjuvant-chemotherapy-for-advanced-epithelial-ovarian-cancer
#7
Andrew Phillips, Kavita Singh, Rachel Pounds, Sudha Sundar, Sean Kehoe, James Nevin, Ahmed Elattar, Janos Balega
The aim of this study was to determine whether the age-adjusted Charlston co-morbidity index (ACCI) can predict post-operative complications, adjuvant chemotherapy usage and overall survival (OS) in patients with advanced epithelial ovarian cancer (AOC) treated with neoadjuvant chemotherapy (NACT). A review was performed of all cytoreductive surgeries performed between 16/8/07-3/2/14 for AOC at a UK Cancer Centre. All surgeries were stratified by ACCI into three groups: Low (0-1), Intermediate (2-3) and High (≥4)...
July 25, 2017: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/28741260/the-androgen-receptor-supports-tumor-progression-after-the-loss-of-ovarian-function-in-a-preclinical-model-of-obesity-and-breast-cancer
#8
Elizabeth A Wellberg, L Allyson Checkley, Erin D Giles, Stevi J Johnson, Robera Oljira, Reema Wahdan-Alaswad, Rebecca M Foright, Greg Dooley, Susan M Edgerton, Sonali Jindal, Ginger C Johnson, Jennifer K Richer, Peter Kabos, Ann D Thor, Pepper Schedin, Paul S MacLean, Steven M Anderson
The androgen receptor (AR) has context-dependent roles in breast cancer growth and progression. Overall, high tumor AR levels predict a favorable patient outcome, but several studies have established a tumor promotional role for AR, particularly in supporting the growth of estrogen receptor positive (ER-positive) breast cancers after endocrine therapy. Our previous studies have demonstrated that obesity promotes mammary tumor progression after ovariectomy (OVX) in a rat model of postmenopausal breast cancer...
July 24, 2017: Hormones & Cancer
https://www.readbyqxmd.com/read/28740958/the-outcomes-of-intestinal-resection-during-debulking-surgery-for-ovarian-cancer
#9
Serdar Gökay Terzioğlu, Murat Özgür Kılıç, Nilüfer Çetinkaya, Eralp Baser, Tayfun Güngör, Cevdet Adıgüzel
OBJECTIVE: To evaluate the clinical and surgical outcomes of intestinal resection during primary debulking surgery for ovarian cancer. MATERIAL AND METHODS: This retrospective study was conducted at Zekai Tahir Burak Women's Health Training and Research Hospital between 2009 and 2013. The patients who underwent intestinal resection during debulking surgery for stage 3 ovarian cancer were included in the analysis. Data regarding patient age, body mass index, tumor histology, disease stage, the site of intestinal resection, all postoperative complications, duration of intensive care unit admission and hospital stay were collected and analyzed...
2017: Turk J Surg
https://www.readbyqxmd.com/read/28740747/in-vitro-assessment-of-anti-proliferative-effect-induced-by-%C3%AE-mangostin-from-cratoxylum-arborescens-on-hela-cells
#10
Aisha I El Habbash, Najihah Mohd Hashim, Mohamed Yousif Ibrahim, Maizatulakmal Yahayu, Fatima Abd Elmutaal Omer, Mashitoh Abd Rahman, Noraziah Nordin, Gwendoline Ee Cheng Lian
Natural medicinal products possess diverse chemical structures and have been an essential source for drug discovery. Therefore, in this study, α-mangostin (AM) is a plant-derived compound was investigated for the apoptotic effect on human cervical cancer cells (HeLa). The cytotoxic effects of AM on the viability of HeLa and human normal ovarian cell line (SV40) were evaluated by using MTT assay. Results showed that AM inhibited HeLa cells viability at concentration- and time-dependent manner with IC50 value of 24...
2017: PeerJ
https://www.readbyqxmd.com/read/28740577/egfr-as-a-prognostic-biomarker-and-therapeutic-target-in-ovarian-cancer-evaluation-of-patient-cohort-and-literature-review
#11
Christine Mehner, Ann L Oberg, Krista M Goergen, Kimberly R Kalli, Matthew J Maurer, Aziza Nassar, Ellen L Goode, Gary L Keeney, Aminah Jatoi, Derek C Radisky, Evette S Radisky
BACKGROUND: Limited effectiveness of therapeutic agents targeting epidermal growth factor receptor (EGFR) in clinical trials using unselected ovarian cancer patients has prompted efforts to more effectively stratify patients who might best benefit from these therapies. A series of studies that have evaluated immunohistochemical (IHC) staining of EGFR in ovarian cancer biopsies has produced unclear results as to the utility of this measure as a prognostic biomarker. Here, we used one of the largest, single institution cohorts to date to determine possible associations of EGFR expression with patient outcome...
May 2017: Genes & Cancer
https://www.readbyqxmd.com/read/28740454/genetic-counselling-brca1-2-status-and-clinico-pathologic-characteristics-of-patients-with-ovarian-cancer-before-50-years-of-age
#12
Mirjam Cvelbar, Marko Hocevar, Srdjan Novakovic, Vida Stegel, Andraz Perhavec, Mateja Krajc
BACKGROUND: In Slovenia like in other countries, till recently, personal history of epithelial ovarian cancer (EOC) has not been included among indications for genetic counselling. Recent studies reported up to 17% rate of germinal BRCA1/2 mutation (gBRCA1/2m) within the age group under 50 years at diagnosis. The original aim of this study was to invite to the genetic counselling still living patients with EOC under 45 years, to offer gBRCA1/2m testing and to perform analysis of gBRCA1/2m rate and of clinico-pathologic characteristics...
June 2017: Radiology and Oncology
https://www.readbyqxmd.com/read/28739799/lgr5-receptor-promotes-cell-cell-adhesion-in-stem-cells-and-colon-cancer-cells-via-the-iqgap1-rac1-pathway
#13
Kendra S Carmon, Xing Gong, Jing Yi, Ling Wu, Anthony Thomas, Catherine M Moore, Ikuo Masuho, David J Timson, Kirill A Martemyanov, Qingyun J Liu
Leucine rich repeat containing G protein coupled receptor 5 (LGR5) is a bona fide marker of adult stem cells in several epithelial tissues, most notably in the intestinal crypts and is highly upregulated in many colorectal, hepatocellular, and ovarian cancers. LGR5 activation by R-spondin (RSPO) ligands potentiates Wnt/β-catenin signaling in vitro, yet deletion of LGR5 in stem cells has little or no effect on Wnt/β-catenin signaling or cell proliferation in vivo. Remarkably, modulation of LGR5 expression has a major impact on the actin cytoskeletal structure and cell adhesion in the absence of RSPO stimulation, but the molecular mechanism is unclear...
July 24, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/28739735/knockdown-of-epha1-using-crispr-cas9-suppresses-aggressive-properties-of-ovarian-cancer-cells
#14
Yuxin Cui, B O Wu, Valentina Flamini, Bronwen A J Evans, Deshan Zhou, Wen G Jiang
BACKGROUND/AIM: Overexpression of erythropoietin-producing hepatocellular A1 (EPHA1), a member of the EPH super family, is frequently observed in various cancer types. The dysregulated interaction of EPHA1 with its ligand Ephrin A1 has been linked to the progression of ovarian cancer (OC). However, the contribution of EPHA1 in the regulation of the aggressive properties of OC cells remains unknown. MATERIALS AND METHODS: In this study we investigated the differential expression of EPHA1 in human OC cells...
August 2017: Anticancer Research
https://www.readbyqxmd.com/read/28739682/lower-body-lymphedema-in-patients-with-gynecologic-cancer
#15
REVIEW
Nicoletta Biglia, Valentina Zanfagnin, Alberto Daniele, Elisabetta Robba, Valentina E Bounous
Lower body lymphedema is a chronic condition and a significant cause of morbidity following treatment of gynecologic cancer that strongly impacts patients' quality of life (QoL). Most studies on secondary lymphedema have been performed on the upper limb after breast cancer treatment and much less is known about lower body lymphedema after gynecologic malignancies. This review focuses on secondary lymphedema due to gynecologic cancer treatment, analyzing its incidence in the different types of gynecologic cancer, diagnosis, risk factors, impact on QoL and treatment...
August 2017: Anticancer Research
https://www.readbyqxmd.com/read/28738876/enterolactone-has-stronger-effects-than-enterodiol-on-ovarian-cancer
#16
Huidi Liu, Jianrui Liu, Siwen Wang, Zheng Zeng, Ting Li, Yongfang Liu, Emilio Mastriani, Qing-Hai Li, Hong-Xia Bao, Yu-Jie Zhou, Xiaoyu Wang, Sijing Hu, Shan Gao, Yingying Qi, Zhihang Shen, Hongyue Wang, Miao Yu, Tingting Gao, Randal N Johnston, Shu-Lin Liu
BACKGROUND: Ovarian cancer is one of the three leading gynecological malignancies, characterized by insidious growth, highly frequent metastasis, and quick development of drug resistance. As a result, this disease has low 5-year survival rates. Estrogen receptor inhibitors were commonly used for the treatment, but only 7% to 18% of patients respond to anti-estrogen therapies. Therefore, more effective therapies to inhibit estrogen-related tumors are urgently needed. Recently, phytoestrogens, such as lignans with estrogen-like biological activities, have attracted attention for their potential effects in the prevention or treatment of estrogen-related diseases...
July 24, 2017: Journal of Ovarian Research
https://www.readbyqxmd.com/read/28738860/germline-emsy-sequence-alterations-in-hereditary-breast-cancer-and-ovarian-cancer-families
#17
Kirsi M Määttä, Riikka Nurminen, Minna Kankuri-Tammilehto, Anne Kallioniemi, Satu-Leena Laasanen, Johanna Schleutker
BACKGROUND: BRCA1 and BRCA2 mutations explain approximately one-fifth of the inherited susceptibility in high-risk Finnish hereditary breast and ovarian cancer (HBOC) families. EMSY is located in the breast cancer-associated chromosomal region 11q13. The EMSY gene encodes a BRCA2-interacting protein that has been implicated in DNA damage repair and genomic instability. We analysed the role of germline EMSY variation in breast/ovarian cancer predisposition. The present study describes the first EMSY screening in patients with high familial risk for this disease...
July 24, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28738539/lncrna-ab073614-regulates-proliferation-and-metastasis-of-colorectal-cancer-cells-via-the-pi3k-akt-signaling-pathway
#18
Yanan Wang, Haoyu Kuang, Jinfang Xue, Liya Liao, Fang Yin, Xiaojun Zhou
The expression profiles of long noncoding RNAs (lncRNAs) in colorectal cancer (CRC) have remained unclear. LncRNA AB073614 is known to be upregulated in ovarian cancer and glioma tissues, and is associated with the occurrence and progression of those cancers. In the present study, we investigated the lncRNA AB073614 gene expression patterns in CRC cell lines and tissue samples from CRC patients, and then analyzed them for possible associations with various clinicopathological characteristics. Furthermore, the roles played by lncRNA AB073614 in CRC cell proliferation, apoptosis, cell cycle progression, migration, and invasion were examined in vitro by using gene knockdown and overexpression techniques...
July 20, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28738361/expression-intracellular-localization-and-prognostic-value-of-plasminogen-activator-inhibitor-1-and-pai-1-rna-binding-protein-1-in-primary-and-recurrent-ovarian-cancer-a-study-of-the-tumor-bank-ovarian-cancer-network
#19
Dominique Koensgen, Matthias B Stope, Ivana Tuerbachova, Daniela Bruennert, Thomas Kohlmann, Ioana Braicu, Jalid Sehouli, Carsten Denkert, Silvia Darb-Esfahani, Elmar Stickeler, Dumitru Sofroni, Edgar Dahl, Alexander Mustea
BACKGROUND: The plasminogen activator system plays a key role in ovarian cancer (OC) tumor progression. The plasminogen activator inhibitor type 1 (PAI-1) and the recently identified PAI-1 RNA binding protein 1 (PAI-RBP1) are primary regulators of plasminogen activation and thus are putative biomarkers for OC progression. METHODS: One hundred fifty six OC patients were analyzed to identify the presence of PAI-1 and PAI-RBP1 and subsequently correlated to clinicopathological parameters...
July 22, 2017: Gynecologic and Obstetric Investigation
https://www.readbyqxmd.com/read/28738296/mental-distress-quality-of-life-and-social-support-in-recurrent-ovarian-cancer-patients-during-active-chemotherapy
#20
Qiang Wen, Zhuyan Shao, Ping Zhang, Tao Zhu, Dan Li, Shihua Wang
BACKGROUND: Anxiety and depression are common sources of mental distress experienced by ovarian cancer patients. The purpose of this study was to identify changes in levels of mental distress during active chemotherapy, to characterize the impact of these changes on quality of life (QOL), and to study the potential buffering effect of social support in recurrent ovarian cancer patients. METHODS: Anxiety and depression were assessed at baseline and three months after initiation of active chemotherapy using hospital anxiety and depression scale (HADS)...
July 6, 2017: European Journal of Obstetrics, Gynecology, and Reproductive Biology
keyword
keyword
98453
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"